NCT05141058View on ClinicalTrials.gov

T Cell Therapy Opposing Novel COVID-19 Infection in Immunocompromised Patients

PHASE1RecruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

October 19, 2021

Primary Completion Date

November 1, 2025

Study Completion Date

December 15, 2027

Conditions
SARS-CoV-2 Infection
Interventions
BIOLOGICAL

Coronavirus-specific T cell (CST)

Participants will receive donor-derived CSTs for prevention of SARS-CoV-2 infection after HSCT (≥28 days and \<4 months after hematopoietic stem cell transplantation (HSCT).

Trial Locations (2)

20010

RECRUITING

Children's National Hospital, Washington D.C.

21287

RECRUITING

The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore

Sponsors
All Listed Sponsors
lead

Children's National Research Institute

OTHER